Every 8-K that Biomea Fusion, Inc. (BMEA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BMEA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BMEA filings page.
Biomea Fusion, a clinical-stage diabetes and obesity medicines company, reported results for the quarter ended June 30, 2026 and highlighted progress across its pipeline. Two Phase II COVALENT-211 and -212 trials of icovamenib in Type 2 diabetes are enrolling, with 26-week data expected in the first and second quarters of 2027, and a Phase I GLP-131 obesity trial of BMF-650 is on track to deliver initial 28-day weight reduction data in the third quarter of 2026. The company is planning a Phase II trial in recently diagnosed Type 1 diabetes and initiated a research collaboration with the University of Leicester to test icovamenib plus semaglutide in obesity. Cash runway is projected into the second quarter of 2027.
For the second quarter of 2026, net loss attributable to common stockholders was $8.3 million versus $20.7 million a year earlier, and first-half net loss was $20.7 million versus $50.0 million. R&D expenses fell to $9.1 million from $16.6 million, and G&A expenses to $3.6 million from $4.7 million, largely reflecting reduced headcount and lower external and facility costs. Cash, cash equivalents and restricted cash totaled $35.2 million as of June 30, 2026.
Biomea Fusion, Inc. reported the results of its Annual Meeting of Stockholders held on June 10, 2026. Holders of 72,299,440 common shares were entitled to vote, and 43,924,456 shares were present or represented by proxy.
Stockholders elected Rainer (Ramses) Erdtmann and Eric Aguiar as Class II directors to serve until the 2029 Annual Meeting or until successors are elected and qualified. Their elections included broker non-votes totaling 20,107,625 shares.
Stockholders also ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 40,209,966 votes for, 3,561,734 against, and 152,756 abstentions.
Biomea Fusion reported first quarter 2026 results and clinical progress in its diabetes and obesity programs. The company is advancing icovamenib, a potential first-in-class oral menin inhibitor for type 1 and type 2 diabetes, and BMF-650, an oral GLP-1 RA candidate for obesity.
Chronic toxicology studies for icovamenib in two species were successfully completed, supporting chronic clinical dosing. In the Phase II COVALENT-112 trial in type 1 diabetes, patients on 200 mg icovamenib showed a 52% increase from baseline in mean C-peptide AUC at Week 12 and mean C-peptide AUC was largely preserved through Week 52 with about a 7% decline. Two Phase II T2D trials (COVALENT-211 and -212) and the Phase I GLP-131 obesity study are ongoing, with 26-week T2D topline data expected in the fourth quarter of 2026 and initial 28-day obesity data in the second quarter of 2026.
Financially, Biomea ended March 31, 2026 with $45.1 million in cash, cash equivalents and restricted cash and projects cash runway into the first quarter of 2027. Net loss narrowed to $12.4 million from $29.3 million a year earlier as R&D expenses fell to $9.1 million from $22.9 million and G&A expenses declined to $3.7 million from $6.8 million, reflecting lower external costs and headcount.
Biomea Fusion, Inc. reported topline 52‑week results from its Phase 2 COVALENT‑112 trial of icovamenib in adults with type 1 diabetes. In patients diagnosed within 0–3 years and treated with 200 mg once daily for 12 weeks, mean C‑peptide area under the curve increased by 52% at Week 12 (p<0.001; n=5), indicating a statistically robust rise in endogenous insulin secretion.
After stopping treatment, mean C‑peptide AUC in this cohort showed only about a 7% decline from baseline by Week 52, suggesting durability of effect. Patients with 3–15 years’ disease duration generally preserved C‑peptide through Week 52. Icovamenib was generally well tolerated over the 52‑week observation period, with no new or unexpected safety signals. The company plans a new Phase 2 trial in patients diagnosed within 3 years, testing extended 200 mg dosing for up to 6 or 12 months and exploring combination with an immunosuppressive JAK inhibitor at four U.S. diabetes centers.
Biomea Fusion reported full-year 2025 results and highlighted rapid progress in its diabetes and obesity pipeline. The company posted a net loss of $61.8 million, significantly narrower than $138.4 million in 2024, as research and development expenses fell to $62.0 million from $118.1 million following a strategic focus on core metabolic programs.
As of December 31, 2025, Biomea held $56.2 million in cash, cash equivalents and restricted cash and projects a cash runway into the first quarter of 2027. Clinically, lead menin inhibitor icovamenib showed durable 52‑week HbA1c reductions of about 1.2% in difficult‑to‑treat type 2 diabetes subgroups, with no treatment‑related serious adverse events or discontinuations.
The company initiated two Phase II icovamenib trials in type 2 diabetes with 26‑week endpoints and expects data in the fourth quarter of 2026, and completed 52‑week follow‑up in a Phase II type 1 diabetes study with data expected in the second quarter of 2026. Biomea also advanced oral GLP‑1 candidate BMF‑650 into the Phase I GLP‑131 obesity trial, with initial 28‑day weight‑reduction data anticipated in the second quarter of 2026.
Biomea Fusion filed an 8-K to share an updated corporate presentation outlining its pipeline for diabetes and obesity. The company highlights icovamenib, a potential first-in-class oral menin inhibitor designed to restore beta-cell function in type 2 diabetes, with two Phase II trials (COVALENT-211 and COVALENT-212) underway and 26-week primary endpoint data anticipated in 4Q 2026. Earlier Phase IIa data showed durable HbA1c reductions and increased C-peptide up to 52 weeks after a 12-week course, along with a generally favorable safety profile. Biomea also presents BMF-650, an investigational next-generation oral GLP-1 receptor agonist for obesity that achieved up to about 15% weight loss over 28 days in obese monkeys, with Phase I 28-day weight reduction data in obese volunteers expected in 2Q 2026. The company states it is funded through key readouts for icovamenib and BMF-650 into Q1 2027 and emphasizes large target populations across insulin-deficient diabetes, GLP-1 inadequate responders, and obesity.
Biomea Fusion, Inc. reported that it presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 and made the associated slide deck available on its website. The company also updated its broader corporate investor presentation, which it plans to use with investors, analysts and other third parties.
Both the conference presentation (Exhibit 99.1) and the corporate presentation (Exhibit 99.2) are included as exhibits and are being furnished rather than filed, meaning they are not subject to certain Exchange Act liabilities or automatically incorporated into other securities filings. The company highlights that these materials contain forward-looking statements about its product candidates, clinical programs, regulatory plans and anticipated trial data, and emphasizes that actual results may differ due to clinical, regulatory and operational risks described in its SEC reports.
Biomea Fusion, Inc. (BMEA) furnished a press release announcing its financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 to a current report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The company notes that the information provided under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act.
Biomea Fusion, Inc. filed an Form 8-K reporting several exhibits tied to a securities offering and related legal opinions. The filing lists an Underwriting Agreement dated October 6, 2025 naming Jefferies LLC as representative, forms for a Pre-Funded Warrant and a Common Stock Warrant, and an opinion and consent from Goodwin Procter LLP (consent included in Exhibit 5.1). The company also attached two press releases dated October 6, 2025 and October 7, 2025 and an interactive XBRL cover page. The filing is signed by the company on October 7, 2025.
Biomea Fusion, Inc. reported new 52-week results from its Phase II COVALENT-111 trial of icovamenib in adults with type 2 diabetes. The topline efficacy analysis focused on 163 patients who completed at least 80% of planned dosing and were on one or more antihyperglycemic drugs at baseline.
Among a prespecified subgroup of 10 severe insulin-deficient patients treated for 12 weeks, icovamenib produced a durable 1.2% reduction in HbA1c through Week 52, with Arm B (6 patients; 100mg once daily for 12 weeks) showing a 1.5% HbA1c reduction, both with p=0.01. In 11 participants already on GLP-1-based therapy but not at glycemic targets, 8 or 12 weeks of icovamenib led to a 1.3% HbA1c reduction (p=0.05) sustained to Week 52.
Icovamenib was generally well tolerated over 52 weeks, with no treatment-related serious adverse events or discontinuations reported. The company outlines plans for additional Phase II studies, including a Phase IIb trial in severe insulin-deficient type 2 diabetes and a Phase II trial in patients on GLP-1 therapy, both expected to initiate in the fourth quarter of 2025.
Biomea Fusion, Inc. (Nasdaq: BMEA) filed an 8-K disclosing that on June 17, 2025 it executed an Amended and Restated Underwriting Agreement with Jefferies LLC to conduct an underwritten equity offering. The transaction consists of (i) 19,450,000 newly issued common shares, (ii) 550,000 pre-funded warrants (exercise price $0.0001) issued in lieu of common shares to certain investors, and (iii) 20,000,000 accompanying common-stock warrants. The company also granted the underwriters a 30-day option to purchase up to an additional 3,000,000 common shares and/or warrants.
Pricing & Structure: Each common share plus warrant unit was priced at $2.00; each pre-funded warrant plus warrant unit at $1.9999, reflecting the $0.0001 exercise price embedded in the pre-funded warrant. The accompanying common-stock warrants carry an initial exercise price of $2.50 per share, are immediately exercisable, and expire 18 months after issuance. Both warrant classes include standard ownership caps (4.5%–14.99%) and “fundamental transaction” protections that allow holders to receive equivalent consideration or Black-Scholes cash value upon a change-of-control event.
Proceeds: Management estimates net proceeds of approximately $37.1 million after underwriting discounts, commissions and expenses. If the 3.0 million overallotment option is fully exercised, net proceeds would rise to approximately $42.7 million. Securities were issued off the company’s effective Form S-3 shelf (File No. 333-267884) and are covered by prospectus supplements dated June 17, 2025.
Key Takeaways for Investors:
- The raise increases liquidity by up to $42.7 million but introduces immediate dilution via 19.45 million new shares and potential dilution from up to 20 million warrant shares plus a 3 million share allotment option.
- Warrant terms—low $2.50 strike and 18-month tenor—suggest near-term overhang yet may facilitate rapid capital inflow if the stock trades above the strike.
- Standard indemnification, covenants and limitation of warrant exercises above preset beneficial-ownership thresholds are included.
Biomea Fusion, Inc. (NASDAQ: BMEA) filed an 8-K on 17 June 2025 disclosing a materially dilutive capital raise. The company entered into an Underwriting Agreement with Jefferies LLC covering an underwritten public offering of (i) 19,450,000 shares of common stock, (ii) 550,000 pre-funded warrants (each equivalent to one share at a $0.0001 exercise price) and (iii) 20,000,000 accompanying common-stock purchase warrants.
Pricing & structure: • Each share+accompanying warrant unit priced at $2.00. • Each pre-funded warrant+accompanying warrant unit priced at $1.9999 (reflecting the $0.0001 exercise price). • Each accompanying warrant is exercisable immediately at $2.50 and expires 18 months after issuance. • Underwriters have a 30-day option to purchase up to an additional 3,000,000 shares and/or warrants at the same terms.
Proceeds: The company expects net proceeds of approximately $37.1 million after underwriting discounts and expenses, rising to about $42.7 million if the option is fully exercised. Securities were offered under the shelf registration statement (File No. 333-267884) declared effective 24 Oct 2022; a final prospectus supplement was filed the same day.
Key warrant terms & limitations: • Beneficial ownership limits of 4.99% or 9.99% (holder-selectable) to avoid triggering excess ownership. • Cap can be raised up to 19.99% with 61-days’ notice. • Upon a “fundamental transaction,” warrant holders are entitled to consideration equal to the Black–Scholes value of the unexercised portion.
Use of proceeds is not specified in the filing; however, management highlighted the capital raise in separate press releases (Exhibits 99.1, 99.2). The transaction is expected to close on 20 June 2025, subject to customary conditions.
Overall, the offering strengthens liquidity but introduces potential dilution and warrant overhang, issues that investors must weigh against the improved cash runway.